查看文章

Pharmacotherapy for the management of chronic stable angina has not changed much in the past 10–20 years. Although the use of revascularization has increased, β‐blockers, calcium channel blockers, and long‐acting nitrates are still widely used in the management of patients with chronic stable angina. Despite the demonstrated effectiveness of these agents, a number of patients do not achieve the American College of Cardiology‐American Heart Association goal of freedom from exertional angina attacks. For the first time in more than a decade, a new agent, ranolazine, is available to assist in controlling exertional angina. Ranolazine has a novel mechanism of action of inhibiting the late sodium current during ventricular depolarization. This mechanism contributes to a reduction in intracellular sodium and, therefore, a reduction in intracellular calcium, reducing ischemic injury. Unlike currently available …